A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury.

Trial Profile

A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Hypersomnia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Mar 2012 Additional locations (Germany, Spain) added as reported by European Clinical Trials Database record.
    • 19 Nov 2010 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top